0458 GMT - Wuxi Biologics (Cayman) Inc. is one of the most mentioned companies in the news over the past six hours, according to Factiva data, after it agreed to license T-cell-engaging antibodies to GSK PLC. Wuxi Biologics said Thursday that the deal was for exclusive licenses for up to four TCE antibodies. GSK will make a $40 million up-front payment to Wuxi and up to $1.46 billion in additional payments for R&D and other milestones along with tiered royalties on net sales, Wuxi Biologics said. The Chinese company's Hong Kong shares rose by as much as 7.7% in early trade before the gains eased to 2.5% ahead of the midday trading break. Dow Jones & Co. owns Factiva. (jacques.vanwersch@dowjones.com)

 

(END) Dow Jones Newswires

January 05, 2023 00:13 ET (05:13 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.